The history of the erectile dysfunction drug presents a complex picture for those considering investment. While the initial launch generated significant gains, the expiration of its patent opened the door to cheaper versions, dramatically reducing revenue. This presents a unique risk for drug manufacturers banking on comparable blockbuster products

The story of Viagra, and its creator copyright, presents a intriguing case study for investors. Originally a blockbuster drug, producing billions in income, its intellectual property lapse created a deluge of knock-off medications, significantly eroding its position . While specific pharmaceutical companies may attempt to capitalize on similar cond